Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
Ajouter des filtres








Gamme d'année
1.
Chinese Journal of Biotechnology ; (12): 3820-3827, 2021.
Article Dans Chinois | WPRIM | ID: wpr-921468

Résumé

Bacterial vaginosis (BV) is a disease caused by vaginal microbiota dysbiosis. The conventional antibiotic treatment can aggravate microbial dysbiosis, alter the acid environment of the vagina and lead to drug resistance, thus shows low cure rate and high recurrence rate. This poses significant physiological and psychological burden to the BV patients. Vaginal microbiota transplantation (VMT) is a novel live biotherapeutic approach. It directly engrafts the whole vaginal microbiota from healthy women to the vaginal tract of patients to rapidly reconstruct the vaginal microbiota environment and restore the vaginal health. This article summarizes the development, present challenges, and future directions of using VMT, with the aim to explore new strategies for treatment of BV and promote the clinical use of VMT.


Sujets)
Femelle , Humains , Dysbiose/thérapie , Microbiote , Vagin , Vaginose bactérienne/thérapie
3.
Clin. biomed. res ; 34(3): 245-252, 2014. ilus
Article Dans Anglais | LILACS | ID: biblio-834470

Résumé

Several trillions of bacteria, distributed among more than 1,000 species, are natural inhabitants of the human intestinal tract and constitute what is now known as the gut microbiota. Although its composition varies within and between individuals with age, diet, and health status, it is becoming increasingly recognized that imbalances in the bacterial microbiota (dysbiosis) are linked to a number of conditions such as antibiotic-associated diarrhea, inflammatory bowel disease, and obesity, among others. Fecal transplantation where a preparation of stool from a microbiologically screened donor is administered into the colon of an affected recipient has been shown to be highly effective for the treatment of recurrent Clostridium difficile infection. Several trials of this therapy are now underway for gut dysbiosis in a number of patient disease groups raising concerns on the risk of transmission of infectious agents from donor to recipient, possible long-term adverse consequences of treatment, and effective regulation of the stool material used for the procedure. A worrying aspect is the emergence of private stool banks providing samples to the general public for self-administration.


Sujets)
Humains , Dysbiose/microbiologie , Dysbiose/thérapie , Maladies inflammatoires intestinales/thérapie , Microbiote , Biothérapie/méthodes , Biothérapie , Biobanques , Clostridioides difficile , Sélection de donneurs , Maladies inflammatoires intestinales/microbiologie , Maladies inflammatoires intestinales/traitement médicamenteux , Fèces/microbiologie , Intestins/microbiologie , Biothérapie/effets indésirables
SÉLECTION CITATIONS
Détails de la recherche